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Loss of lung function is the primary cause of CF mortality, and RLFD is a robust
predictor of survival (Statist Med 2002;21:1271−87). RLFD (as FEV1 % pred/yr)
is a more meaningful measure than sustained improvement in lung function,
but there is less experience with RLFD as an endpoint. We have used recent
epidemiologic data (J Pediatr 2007;151:134−9, Ped Pulm 2007; S30:345) to develop
a sample size (N) determination model for RLFD studies in 6−17 yr olds with CF.
A mock 500 subject cohort was constructed with distribution of risk variables
(age, FEV1 % pred, PA infection, sex, sputum production, wheeze, and crackles)
comparable to the current US CF population. The cohort was randomized into 2
arms stratiﬁed by age (32% 6−8 yrs, 30% 9−12 yrs, 38% 13−17 yrs). Subject and
group RLFD over 2 yrs were estimated as functions of the presence/absence of risk
factors. This was repeated 200 times each for cohorts of 500, 200, 150, 100, 80,
60, 40, and 20 subjects with risk variables randomly redistributed each iteration.
Mean RLFD was −2.17 FEV1 % pred/yr for the cohort. Boundaries within which
90% of conﬁdence intervals for RLFD point estimates fell were plotted against N
to determine 80% power thresholds to detect given treatment effects. In this cohort,
33 subjects/arm would be required to assure <80% power to detect a 50% reduction
in RLFD, while 18 subjects/arm would be needed to detect a 70% reduction. The
power of this method is that it is sensitive to impacts of speciﬁc risk factors on
RLFD and can be used in conjunction with currently available CF patient registries
to estimate sample size requirements for speciﬁc subsets of CF patients (e.g. having
a speciﬁc CFTR mutation or risk factor).
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Introduction: The UK CF Trust policy for treatment of ﬁrst/new growths of
Pseudomonas aeruginosa (PsA) in an asymptomatic child is 3 weeks of oral
ciproﬂoxacin and 3 months of inhaled colistin. Recent use of an adaptive aerosol
delivery (AAD) device for inhaled colistin has enabled adherence to be monitored
in partnership with families in our clinic. We have investigated the relationship
between adherence to 3 months of inhaled antibiotic therapy, PsA clearance (PsA
culture-negative cough swabs/sputa for 6 months following start of treatment) and
lung function.
Methods: From November 2005, 36 ﬁrst/new growths of PsA in 33 children were
treated with inhaled colistin via an AAD (I-neb, Respironics). Using software
provided by the manufacturers, adherence was analysed over the 3 month treatment
period. Respiratory cultures were routinely taken after three weeks and three months
(and occasionally more frequently). Lung function was performed at the start and
the end of eradication.
Results: Adherence data for 23/36 children have been analysed to date. Overall
mean (SD) adherence to inhaled treatment was signiﬁcantly higher in the evenings
[86.4(28.9)%] than in the mornings [75.5(24.7)%; p = 0.022]. 17/23 (74%) patients
exhibited good adherence (taking >80% of their treatments). Successful PsA
eradication was achieved in 17/23. Adherence and lung function were no better in
those children that eradicated PsA although numbers were small. No relationship
between adherence, PsA clearance and change in lung function was detected.
Conclusions: These data suggest good adherence to inhaled antibiotic treatment
for ﬁrst/new growths of PsA. These preliminary data do not suggest a relationship
between adherence to treatment, PsA clearance and lung function.
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Introduction: Few studies report on adherence in adults with CF, most use
self-report, physician report or medical record review which may overestimate
true adherence. This prospective study assesses concordance between objective
adherence to nebulised therapy [data downloaded from i-neb (Respironics)] and
subjective adherence measured by questionnaire administered to patients, CF doctor,
pharmacist, physiotherapist, dietitian and nurse.
Methods: i-neb stores data of use of nebulisers (date, time, length of nebulised
treatments and details of incomplete treatments). Subjective assessment of adher-
ence was undertaken at clinic and data for 3 months prior to visit downloaded
from ineb. Members of the MDT then completed an adherence questionnaire for
participants. 2 questions on adherence were given: average number nebs/week and
overall % nebulised treatment taken over last 3 months, to assess whether form of
questioning affects accuracy.
Results: Adherence is expressed as % prescribed regimen, descriptive data ex-
pressed as median (range) and agreement between adherence measures assessed
using intra-class correlation coefﬁcient. 68 patients have completed the study to
date. Results are summarised in Table 1. No agreement was found between objective
adherence and self or MDT report.
Conclusion: Self and MDT reporting of adherence is not accurate. This has
implications for studies and clinical practice when assessing and monitoring therapy.
True compliance is lower than previously suggested at 36%, this may have QoL
and cost implications.
Table 1
Average number of nebs/week Overall % nebulisers taken over last 3 months
Patient Pharm Physio Dr Diet Nurse Patient Pharm Physio Dr Diet Nurse Objective
Median% 75 57 50 61 62 57 80 50 53 60 60 60 36
Range 133 100 86 100 79 91 100 100 90 100 78 95 112
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Early treatment of Pseudomonas aeruginosa (Pa) (re)infection can postpone chronic
infection.
Aim: compare 2 Pa antibiotic (AB) eradication regimens.
Method: CF children (0−18 years) with new isolation of Pa (sputum or cough
swabs) were prospectively randomized to treatment with inhaled TOBI® (300mg
bid for 28 days) vs 3 months combination therapy with inhaled Colistineb® (2 milj
U bid) + oral ciproﬂoxacin (10mg/kg tid) (CC). Monthly airway cultures were taken
for 6 months, then 3 monthly. Positive Pa culture in the ﬁrst 6 months was deﬁned
as treatment failure. Patients were then switched to the other arm or treated with
IV AB if clinically indicated. Secondary outcomes were: Pa antibodies (Ab), IgG,
lung function, weight and time to Pa relapse.
Results: data on 26 patients are available. Median age was 9 years (0−16); median
FEV1 at inclusion 90% predicted. For 7 patients this was the ﬁrst Pa isolation
‘ever’ (TOBI: 4; CC: 3). For the remaining, median time since previous Pa was 23
months (range 6−79). CC treatment failed in 3 out of 10 patients (1 needing IV
AB), 2 patients were non-evaluable. For 16 TOBI treated patients 8 failed (2 needing
IV), 1 was non-evaluable. Taking into account switches to the other treatment arm,
eradication succeeded in 9 of 14 CC and 8 of 17 T (ns).
Pa Ab were raised in 1 patient at baseline and returned negative after successful
treatment. At >1 year follow-up 3 patients were chronically Pa colonized (1 from
the CC group, 2 of the TOBI group); in 1 patient Pa Ab levels became +ve.
Conclusion: Success rate of short term eradication in new Pa isolation was low.
However, use of cough swabs rather then BAL (Gibson 2007) may overestimate
lower airway infection. Low patient numbers limit comparison between the 2 regi-
mens yet.
